Home | Log in or Sign Up for full access | Tracked Organizations | Recent Tracked Activities

Recent Activities

Activities between Nov. 15, 2024, 7:30 p.m. and Nov. 22, 2024, 7:30 p.m. from: Molecular Diagnostic Products And Services.

Click on a document link to see the original source document. Click on the name of an organization to see more organization linkages and timelines.


Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina's Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2

Document Date: Nov. 20, 2024, 9:30 p.m. / Source: GlobeNewswire
Activity Class: PartnershipActivity
Partnership: Document Extract: SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) - Myriad Genetics, Inc. (NASDAQ: MYGN) , a leader in genetic testing and precision medicine, announced updates to its agreement with Illumina Inc. (NASDAQ: ILMN) , a global leader in DNA sequencing and array - based technologies. Myriad's gold-standard Genomic Instability Score (GIS) to determine Homologous Recombination Deficiency (HRD) will be reported for all samples analyzed with Illumina's updated research assay, TruSight™ Oncology 500 v2 (TSO 500 v2) . Previously, GIS to determine HRD was only available as a separate product. As a result, a broad array of cancer types will receive GIS results and their HRD status. " We are pleased to expand our collaboration with Illumina and combine the two companies' technologies to create what we believe is the most advanced and complete gene panel to enable comprehensive genomic profiling ," said Patrick Burke, PhD, EVP of Strategy and Innovation, Myriad Genetics.
Document Source: https://www.globenewswire.com/news-release/2024/11/20/2984793/15459/en/Myriad-Genetics-Announces-Incorporation-of-its-Proprietary-HRD-platform-in-Illumina-s-Updated-Comprehensive-Gene-Panel-Assay-TruSight-Oncology-500-v2.html (archive.org page / archive.org listing)


Ikonisys Completed a Capital Increase Through a Private Placement

Document Date: Nov. 19, 2024, 7 a.m. / Source: Business Wire
Activity Class: CorporateFinanceActivity / Type: Ipo
Vendor: Document Extract: Ikonisys SA (Euronext Growth Paris: ALIKO) , a company specializing in the early and accurate detection of cancers through a unique, fully automated solution for medical analysis laboratories (the "Issuer") , today announces that it has completed a capital increase of €200k, by way of a private placement.
Document Source: https://www.businesswire.com/news/home/20241118467529/en/Ikonisys-Completed-a-Capital-Increase-Through-a-Private-Placement (archive.org page / archive.org listing)


Ikonisys Completed a Capital Increase Through a Private Placement

Document Date: Nov. 19, 2024, 7 a.m. / Source: Business Wire
Activity Class: CorporateFinanceActivity / Type: Investment
Target: Document Extract: Ikonisys Completed a Capital Increase Through a Private Placement.
Document Source: https://www.businesswire.com/news/home/20241118467529/en/Ikonisys-Completed-a-Capital-Increase-Through-a-Private-Placement (archive.org page / archive.org listing)


Ikonisys Group enters Central America Market through a Partnership and Distribution Agreement with Green Med Panama

Document Date: Nov. 18, 2024, 6:30 a.m. / Source: Business Wire
Activity Class: PartnershipActivity / Region: Republic of Panama
Partnership: Document Extract: Regulatory News: Ikonisys SA (Euronext Growth Paris: ALIKO) , a company specializing in the early and accurate detection of cancers through a unique fully automated solution for medical analysis laboratories, today announces the signing of a distribution agreement with Green Med, a major distributor of medical devices in Panama and Central America. This collaboration is part of a strategic initiative, which aims at bringing innovative cytological and oncological diagnostics to the region, based on four core initiatives. The first step of the plan focuses on certification and importation of Ikonisys Group's products into Panama, leveraging the region's logistical and operational advantages. Panama's strategic position as a logistics hub will enable streamlined distribution and access to Ikonisys Group's products across Central America (including Costa Rica, Nicaragua, Honduras, Salvador, Guatemala and Belize).
Document Source: https://www.businesswire.com/news/home/20241117538354/en/Ikonisys-Group-enters-Central-America-Market-through-a-Partnership-and-Distribution-Agreement-with-Green-Med-Panama (archive.org page / archive.org listing)


Ikonisys Group enters Central America Market through a Partnership and Distribution Agreement with Green Med Panama

Document Date: Nov. 18, 2024, 6:30 a.m. / Source: Business Wire
Activity Class: PartnershipActivity
Partnership: Document Extract: Ikonisys Group enters Central America Market through a Partnership and Distribution Agreement with Green Med Panama. Regulatory News: Ikonisys SA (Euronext Growth Paris: ALIKO) , a company specializing in the early and accurate detection of cancers through a unique fully automated solution for medical analysis laboratories, today announces the signing of a distribution agreement with Green Med, a major distributor of medical devices in Panama and Central America. This collaboration is part of a strategic initiative, which aims at bringing innovative cytological and oncological diagnostics to the region, based on four core initiatives. The first step of the plan focuses on certification and importation of Ikonisys Group's products into Panama, leveraging the region's logistical and operational advantages.
Document Source: https://www.businesswire.com/news/home/20241117538354/en/Ikonisys-Group-enters-Central-America-Market-through-a-Partnership-and-Distribution-Agreement-with-Green-Med-Panama (archive.org page / archive.org listing)


Tagomics Announces a Multiomic Profiling Co-Marketing Agreement with Agilent

Document Date: Nov. 20, 2024, 9:45 a.m. / Source: Business Wire
Activity Class: PartnershipActivity
Partnership: Document Extract: To showcase the potential of this combined approach, Tagomics has signed a co-marketing agreement with Agilent Technologies, and launched a technology access program which allows select customers to experience the enhanced capabilities of the combined platform ahead of the broader market. Customers will benefit from more comprehensive insights into the mechanisms driving disease, opening the door to novel diagnostic and therapeutic strategies. Dr Jack Kennefick, CEO and co-founder of Tagomics said: "We 're pleased to be working with Agilent Technologies to bring select customers the combined capabilities of our respective platforms, unified in Tagomics' Interlace multiomic workflow. Through this collaboration, we look forward to empowering customers with deeper biological insights and accelerating the development of innovative diagnostic and therapeutic solutions ." Ronda Allen, general manager of Genomics at Agilent Technologies commented: "Through our agreement, our customers will have access to Tagomics' Interlace platform and advanced bioinformatics software, enabling simultaneous genetic and genome-wide epigenomic profiling.
Document Source: https://www.businesswire.com/news/home/20241120251260/en/Tagomics-Announces-a-Multiomic-Profiling-Co-Marketing-Agreement-with-Agilent (archive.org page / archive.org listing)

Archive.org page links will work if the page has already been archived by archive.org, but we can't guarantee which pages archive.org has archived so far.

Treat sameAsNameOnly relationship as same? Yes (Turn Off)

Site Stats | About (includes privacy and cookie notices)
(c) by 1145, 2023-2024. Data licensed under the Open Database License. Please send an email if you need a non-share-alike license and/or you need API access.